{"id":"NCT00695955","sponsor":"Takeda","briefTitle":"One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","officialTitle":"A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2008-06-12","resultsPosted":"2011-04-19","lastUpdate":"2011-04-19"},"enrollment":669,"design":{"allocation":"NON_RANDOMIZED","model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan medoxomil with or without add-on chlorthalidone","otherNames":["TAK-491","Edarbi"]},{"type":"DRUG","name":"Azilsartan medoxomil with or without add-on hydrochlorothiazide","otherNames":["TAK-491","Edarbi"]}],"arms":[{"label":"Azilsartan Medoxomil","type":"EXPERIMENTAL"}],"summary":"This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.","primaryOutcome":{"measure":"Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.","timeFrame":"56 weeks.","effectByArm":[{"arm":"Cohort 1","deltaMin":267,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":41,"countries":["United States","Chile","Mexico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":362},"commonTop":["Dizziness","Headache","Fatigue","Upper respiratory tract infection","Urinary tract infection"]}}